Журнал протеомики и биоинформатики

Журнал протеомики и биоинформатики
Открытый доступ

ISSN: 0974-276X

Абстрактный

Rising Antimicrobial Resistance of Pseudomonas aeruginosa Isolated from Clinical Specimens in India

Manu Chaudhary and Anurag Payasi

The rising antibiotic resistance against commonly used drugs is of great concern. Drug susceptibility testing and Polymerase Chain Reaction (PCR) assay were used to determine the antibiotic susceptibility patterns and prevalence of genes encoding extended-spectrum-β-lactamases (ESBLs) and metallo-β-lactamases (MBLs) among 515 isolates of Pseudomonas aeruginosa isolated from various clinical specimens. Susceptibility of isolates to seven antibiotics was tested using disc diffusion method according to the guidelines defined by Clinical Laboratory Standard Institute. Isolates showing resistance to any of the two cephalosporins (ceftriaxone, ceftazidime and cefotaxime) were subjected to PCR for the prevalence of ESBL and MBL gene characterization. Out of the 515 isolates, 235 (45.63%) were considered as ESBL positive; 87 (16.89%) were MBL positive and 74 (14.36%) had co-produced both ESBL and MBL. The frequency of TEM-type, SHV-type and AMP-C type ESBLs were 45.10, 26.0, and 28.93%, respectively. Among the MBLs, the frequency of distribution of NDM-1, IMP-1 and VIM-1 was 24.13, 28.73 and 47.12%, respectively. The rate of susceptibility of ESBL producing P. aeruginosa towards various antibacterial agents were as follows: piperacillin+tazobactam (84.3%), doripenem (83.8%), ceftriaxone plus ethylenediamminetetraacetic acid plus sulbactam; Elores (74.1%), imipenem (66.5%), meropenem (54.7%), ceftazidime (44.8%) and cefepime (28.5%). Isolates harboring MBL and ESBL+MBL genes were resistant to almost all antibiotics except Elores (97.3 and 95.1% susceptibility) and doripenem (11.3 and 19.5% susceptibility). From the above results, it can be concluded that Elores was highly potent against MBL producing P. aeruginosa. However, suceptibility of Elores to ESBL producing P. aeruginosa was comparable to piperacillin plus tazobactam.

Отказ от ответственности: Этот тезис был переведен с использованием инструментов искусственного интеллекта и еще не прошел рецензирование или проверку.
Top